title: [Progressive muscular dystrophies and drug risks].
abstract: Many therapeutic agents are necessary during the evolution of progressive muscular dystrophy to cure intercurrent diseases. Some of them may impair muscular structure and induce rhabdomyolysis, toxic or inflammatory myopathy. Other treatments may produce metabolic and functional alterations or impair cardiac and respiratory functions, yet endanged in progressive muscular dystrophy. They must be contra-indicated or used carefully during progressive muscular dystrophy.
authors: Laboratoire de Pharmacologie, CHU, Lille.
authors: R
authors: R
authors: Bordet
authors: J
authors: J
authors: Caron
authors: A
authors: A
authors: Destée
authors: B
authors: B
authors: Dupuis
mesh_terms: D006801:Humans; D009135:Muscular Diseases / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology; D009136:Muscular Dystrophies / Q000150:complications / Q000503:physiopathology*; D012307:Risk Factors
vernacular_title: Dystrophies musculaires progressives et risques médicamenteux.